Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Since Kevetrin has the ability to chemosensitize, its combination therapy possibilities are endless. We could get an update on K-OC cohort 1 soon since the trial is open-label.

"The Company’s previously reported mechanism of action (MOA) of Kevetrin strongly suggests that Kevetrin has great potential to enhance chemosensitivity. Multiple reports from different laboratories have shown that drugs modulating any of these: p531, HDAC2, c-MYC3(p53:Clin. Can. Research 2009 15, 6495-502; HDAC: Cancer Sci 2008 99, 378-84; c-Myc: Biomed Pharmacother 2015 73, 123-128) has shown enhanced sensitivity to chemotherapeutic drugs. p53 is major determinant of chemosensitivity in humans while mutant p53 proteins can induce drug resistance. Since Kevetrin modulates all of the above molecules, laboratory studies tested the sensitizing ability in mutant p53 cells and tumors which are refractory to chemotherapeutic agents. The combination of Kevetrin with chemotherapy drugs resulted in synergistic apoptosis at a much lower concentrations than with each agent individually. Thus, Kevetrin holds promise to maximize tumor cell killing when used in combination therapies. Laboratory studies conducted by Cellceutix and at leading institutions on the effects of Kevetrin in combination with approved cancer drugs, including studies against renal cancer, pancreatic cancer, ovarian cancer, glioblastoma and acute myeloid leukemia, have delivered promising data supporting the ability of Kevetrin to enhance chemosensitivity."

http://www.cellceutix.com/press-release-2/2016/9/20/cellceutixs-clinical-trial-of-anti-cancer-agent-kevetrin-meeting-its-goals-approaching-end-of-trial?rq=chemosensitivity